Back to Journals Drug Design, Development and Therapy Volume 20 GLP-1 Receptor Agonists in Neurological Disorders: From Mechanisms to Clinical Translation Received 1 April 2026 Accepted for publication 2 June 2026 Published 12 June 2026 Volume 2026:20 613616 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 4 Editor who approved publication: Professor Anastasios Lymperopoulos Pengpeng Li, Yangyang Gao, Wei Liu Department of Neurosurgery, Xian Aerospace Hospital of Northwest University, Xian, Shanxi, 710000, Peoples Republic of China Correspondence: Pengpeng Li, Email [email protected] Wei Liu, Email [email protected] Abstract: Glucagon-like peptide-1 receptor agonists, or GLP-1RAs, have been used for years to treat type 2 diabetes and obesity
Frequently Asked Questions What is the dosing schedule for retatrutide used in clinical trials
2/ How much weight can you lose on Qsymia 3/ What are the side effects of Qsymia
This comparison breaks down what each does, how they differ, and why their combination (CagriSema) may represent the next leap in obesity pharmacotherapy
Critical when titration precision determines both efficacy and tolerability
As the prevalence of obesity continues to rise, effective treatments are urgently needed
